Patents by Inventor Brendan J. CLASSON

Brendan J. CLASSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
    Patent number: 12291571
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: May 6, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
  • METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR
    Publication number: 20230272085
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Application
    Filed: July 13, 2022
    Publication date: August 31, 2023
    Inventors: Ana KOSTIC, Ludmila KELLY, Xia LIU, Brendan J. CLASSON, Allen RADIN
  • Methods of treating eosinophilic esophagitis by administering an antibody which inhibits interleukin-4 receptor (IL-4R)
    Patent number: 11421036
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 23, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
  • METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR
    Publication number: 20200332014
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 22, 2020
    Inventors: Ana KOSTIC, Ludmila KELLY, Xia LIU, Brendan J. CLASSON, Allen RADIN
  • Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
    Patent number: 10730948
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: February 7, 2016
    Date of Patent: August 4, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
  • HUMAN ANTIBODIES TO HUMAN TNF-LIKE LIGAND 1A (TL1A)
    Publication number: 20170096491
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 6, 2017
    Inventors: Brendan J. Classon, Dimitris Skokos
  • Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A
    Patent number: 9556277
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: January 31, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Brendan J. Classon, Dimitris Skokos
  • Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
    Patent number: 9533039
    Abstract: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions, e.g., systemic lupus erythematosus.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: January 3, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Brendan J. Classon, Ana Kostic, Xunbao Duan
  • Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
    Publication number: 20160152718
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Application
    Filed: February 7, 2016
    Publication date: June 2, 2016
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon, Allen Radin
  • Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor
    Patent number: 9290574
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: March 22, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ana Kostic, Ludmila Kelly, Xia Liu, Brendan J. Classon
  • Antibodies capable of blocking the interaction between CD48 and a CD48 receptor
    Patent number: 9228014
    Abstract: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: January 5, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Brendan J. Classon, Ana Kostic, Xunbao Duan
  • METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS BY ADMINISTERING AN IL-4R INHIBITOR
    Publication number: 20150017176
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R?) inhibitor such as an anti-IL-4R? antibody.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 15, 2015
    Inventors: Ana KOSTIC, Ludmila KELLY, Xia LIU, Brendan J. CLASSON
  • Human Antibodies to Human TNF-Like Ligand 1A (TL1A)
    Publication number: 20140120109
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
    Type: Application
    Filed: December 31, 2013
    Publication date: May 1, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Brendan J. Classon, Dimitris Skokos
  • Human antibodies to human TNF-like ligand 1A (TL1A)
    Patent number: 8642741
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: February 4, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Brendan J. Classon, Dimitris Skokos
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) USING ANTI-CD48 ANTIBODIES
    Publication number: 20130230533
    Abstract: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions, e.g., systemic lupus erythematosus.
    Type: Application
    Filed: April 18, 2013
    Publication date: September 5, 2013
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: BRENDAN J. CLASSON, ANA KOSTIC, XUNBAO DUAN
  • HUMAN ANTIBODIES TO HUMAN TNF-LIKE LIGAND 1A (TL1A)
    Publication number: 20120114654
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human TNF-like ligand 1A (hTL1A) is provided. The human anti-hTL1A antibodies are useful in treating diseases or disorders associated with TL1A, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Brendan J. Classon, Dimitris Skokos
  • ANTI-CD48 ANTIBODIES AND USES THEREOF
    Publication number: 20120076790
    Abstract: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions.
    Type: Application
    Filed: September 26, 2011
    Publication date: March 29, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Brendan J. CLASSON, Ana Kostic, Xunbao Duan